HAE product, FIRAZYR, to the portfolio.
Sale of non-core assets
- Following the transfer of the relevant marketing consents Shire
recognised previously deferred gains of $4 million arising from the
divestment of non-core products to Laboratorios Almirall S.A
("Almirall") in 2007.
HGT analyst day
Shire is holding an analyst day on November 18, 2008 in Lexington, Massachusetts
Please visit http://www.shire.com for registration and additional information
Dial in details for the live conference call for investors 14:00
GMT/10:00 EDT on October 29, 2008:
UK and International dial in: +44-(0)20-7806-1951
US dial in: +1-718-354-1385
Password/Conf ID: 4688205
Notes to Editors
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: http://www.shire.com
THE "SAFE HARBOR" STATEMENT UNDER THE PRIVAT
|SOURCE Shire Plc|
Copyright©2008 PR Newswire.
All rights reserved